Suppr超能文献

马凡综合征的病理生理学和发病机制。

Pathophysiology and Pathogenesis of Marfan Syndrome.

机构信息

Division of Cardiothoracic Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC, USA.

Division of Cardiothoracic Surgery, Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA.

出版信息

Adv Exp Med Biol. 2021;1348:185-206. doi: 10.1007/978-3-030-80614-9_8.

Abstract

Marfan syndrome (MFS) is a systemic connective tissue disorder that is inherited in an autosomal dominant pattern with variable penetrance. While clinically this disease manifests in many different ways, the most life-threatening manifestations are related to cardiovascular complications including mitral valve prolapse, aortic insufficiency, dilatation of the aortic root, and aortic dissection. In the past 30 years, research efforts have not only identified the genetic locus responsible but have begun to elucidate the molecular pathogenesis underlying this disorder, allowing for the development of seemingly rational therapeutic strategies for treating affected individuals. In spite of these advancements, the cardiovascular complications still remain as the most life-threatening clinical manifestations. The present chapter will focus on the pathophysiology and clinical treatment of Marfan syndrome, providing an updated overview of the recent advancements in molecular genetics research and clinical trials, with an emphasis on how this information can focus future efforts toward finding betters ways to detect, diagnose, and treat this devastating condition.

摘要

马凡综合征(MFS)是一种系统性结缔组织疾病,呈常染色体显性遗传,具有可变的外显率。虽然临床上这种疾病有多种不同的表现,但最危及生命的表现与心血管并发症有关,包括二尖瓣脱垂、主动脉瓣关闭不全、主动脉根部扩张和主动脉夹层。在过去的 30 年中,研究工作不仅确定了负责的遗传位置,而且开始阐明这种疾病的分子发病机制,为治疗受影响个体的看似合理的治疗策略的发展提供了依据。尽管取得了这些进展,但心血管并发症仍然是最危及生命的临床表现。本章将重点介绍马凡综合征的病理生理学和临床治疗,提供分子遗传学研究和临床试验的最新进展概述,重点介绍如何利用这些信息为寻找更好的方法来检测、诊断和治疗这种毁灭性疾病提供依据。

相似文献

1
Pathophysiology and Pathogenesis of Marfan Syndrome.
Adv Exp Med Biol. 2021;1348:185-206. doi: 10.1007/978-3-030-80614-9_8.
3
Marfan syndrome revisited: From genetics to the clinic.
Rev Port Cardiol (Engl Ed). 2020 Apr;39(4):215-226. doi: 10.1016/j.repc.2019.09.008. Epub 2020 May 18.
5
The pathogenesis of aortopathy in Marfan syndrome and related diseases.
Curr Cardiol Rep. 2010 Mar;12(2):99-107. doi: 10.1007/s11886-010-0083-z.
7
miR-29b participates in early aneurysm development in Marfan syndrome.
Circ Res. 2012 Jan 20;110(2):312-24. doi: 10.1161/CIRCRESAHA.111.253740. Epub 2011 Nov 23.
8
Marfan syndrome type II: there is more to Marfan syndrome than fibrillin 1.
Congenit Heart Dis. 2006 Sep;1(5):229-32. doi: 10.1111/j.1747-0803.2006.00040.x.
9
Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes.
Int Heart J. 2016 May 25;57(3):271-7. doi: 10.1536/ihj.16-094. Epub 2016 May 13.
10

引用本文的文献

1
Therapeutic Opportunities of Marfan Syndrome: Current Perspectives.
Drug Des Devel Ther. 2025 Aug 26;19:7365-7379. doi: 10.2147/DDDT.S523571. eCollection 2025.
3
Innovative strategies for bone organoid: Synergistic application and exploration of advanced technologies.
J Orthop Translat. 2025 Aug 14;54:180-198. doi: 10.1016/j.jot.2025.07.010. eCollection 2025 Sep.
4
PU.1 regulation of type 1 dendritic cell function via NF-κB pathway in inhibition of non-small cell lung cancer progression.
J Pharm Anal. 2025 Jul;15(7):101154. doi: 10.1016/j.jpha.2024.101154. Epub 2024 Nov 22.
6
Defective Mitochondrial Respiration in Hereditary Thoracic Aneurysms.
Cells. 2025 May 23;14(11):768. doi: 10.3390/cells14110768.
7
Case Report: A frameshift-and-nonsense mutation and aortic dissection in Marfan syndrome.
Front Cardiovasc Med. 2025 Apr 23;12:1533138. doi: 10.3389/fcvm.2025.1533138. eCollection 2025.
9
Functional analysis of a novel deep intronic variant causing Marfan syndrome in a Chinese patient.
Front Genet. 2025 Mar 19;16:1564824. doi: 10.3389/fgene.2025.1564824. eCollection 2025.

本文引用的文献

3
Increased fracture rate in children and adolescents with Marfan syndrome.
Bone. 2020 Jun;135:115333. doi: 10.1016/j.bone.2020.115333. Epub 2020 Mar 25.
4
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.
Lancet. 2019 Dec 21;394(10216):2263-2270. doi: 10.1016/S0140-6736(19)32518-8. Epub 2019 Dec 10.
5
Trends in spinal deformity surgery in Marfan syndrome.
Spine J. 2019 Dec;19(12):1934-1940. doi: 10.1016/j.spinee.2019.08.005. Epub 2019 Aug 12.
6
Genetic testing for aortopathies: primer for the nongeneticist.
Curr Opin Cardiol. 2019 Nov;34(6):585-593. doi: 10.1097/HCO.0000000000000669.
9
Diffuse Myocardial Fibrosis in Children and Adolescents With Marfan Syndrome and Loeys-Dietz Syndrome.
J Am Coll Cardiol. 2018 Oct 30;72(18):2279-2281. doi: 10.1016/j.jacc.2018.07.095.
10
External Aortic Root Support to Prevent Aortic Dilatation in Patients With Marfan Syndrome.
J Am Coll Cardiol. 2018 Sep 4;72(10):1095-1105. doi: 10.1016/j.jacc.2018.06.053.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验